Cadisegliatin Trial
Phase 3
150
about 2.4 years
18+
50 sites in AR, AZ, CA +17
About this study
This trial is testing whether cadisegliatin, taken as a treatment alongside insulin, can help people with Type 1 Diabetes. Participants will take either cadisegliatin or a placebo for up to 869 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cadisegliatin 800 mg BID
- 2.Take Cadisegliatin 800 mg QD
- 3.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: To assess the change in HbA1c, To assess the effects of treatment on body weight, To assess the incidence of adverse events of special interest, To assess the incidence of treatment emergent adverse events, To assess the incidence of treatment emergent adverse events leading to discontinuation
Endocrinology